Can new drug promise pain relief without peril?
The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...
The American Journal of Managed Care3d
Suzetrigine: First-in-Class Nonopioid Pain Therapy Is Approved by FDA
Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...
Vertex Pharmaceuticals: Strong Buy Rating Driven by Suzetrigine Approval and Promising Market Prospects
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating on January 31.Maximize Your ...
Historic FDA approval marks first nonopioid breakthrough since Clinton era
The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...
Business Wire4d
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
About JOURNAVX™ (suzetrigine) JOURNAVX (suzetrigine) is a first-in-class, oral, non-opioid, highly selective pain signal inhibitor that is selective for NaV1.8 relative to other NaV channels.